AMYT Stock Forecast 2025-2026
Distance to AMYT Price Targets
AMYT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Amryt Pharma (AMYT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AMYT and similar high-potential opportunities.
Latest AMYT Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for AMYT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMYT Analyst Ratings
AMYT Price Target Range
Latest AMYT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMYT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
(AMYT) Competitors
The following stocks are similar to Amryt Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(AMYT) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
(AMYT) Business Model
(AMYT) Latest News & Analysis
Poolbeg Pharma PLC has appointed former Amryt Pharma executives to enhance its management team, aiming to advance its clinical assets under Chairman Cathal Friel's leadership.
The appointment of former Amryt Pharma executives signals Poolbeg's strategic focus on advancing clinical assets, potentially enhancing its value and attractiveness to investors.
Chiesi Farmaceutici has completed the acquisition of Amryt Pharma, enhancing its focus on developing treatments for rare diseases.
Chiesi's acquisition of Amryt enhances its portfolio in rare diseases, potentially increasing revenue and market share, which can positively impact stock performance and investor sentiment.
Amryt Pharma is being acquired for $14.50 per share plus a contingent value right with potential payouts of $1 and $1.50, currently trading at $14.69.
The acquisition price of $14.50 per share is below the current trading price of $14.69, indicating potential investor confidence in the contingent value rights and future payouts.
Amryt Pharma shareholders have approved the acquisition of the company by Chiesi Farmaceutici.
The approval of Amryt Pharma's acquisition by Chiesi Farmaceutici signals a consolidation in the pharmaceutical sector, potentially affecting stock valuations and market dynamics.
Halper Sadeh LLC is investigating the fairness of Chiesi Farmaceutici's proposed acquisition of Amryt Pharma for $14.50 per ADS plus up to $2.50 in contingent value rights.
The investigation into Amryt Pharma's sale could impact stock prices, as fairness concerns may lead to legal challenges, affecting shareholder value and future growth potential.
Amryt Pharma Plc is proposed to be sold to Chiesi Farmaceutici S.p.A. Shareholders will receive $14.50 in cash plus a potential additional $2 via a Contingent Value Right.
The investigation into Amryt Pharma's sale may impact stock prices and investor sentiment as potential legal issues could affect the deal's completion or terms.
Frequently Asked Questions About AMYT Stock
What is 's (AMYT) stock forecast for 2025?
Analyst forecasts for (AMYT) are not currently available. The stock is trading at $0.00.
Is AMYT stock a good investment in 2025?
Analyst ratings for AMYT are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMYT stock?
Price predictions from Wall Street analysts for AMYT are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for AMYT ?
Price targets from Wall Street analysts for AMYT are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for AMYT ?
Price targets from Wall Street analysts for AMYT are not currently available. The stock is trading at $0.00.
What is the overall AMYT consensus from analysts for ?
Analyst ratings for AMYT are not currently available. The stock is trading at $0.00.
How accurate are AMYT stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
